Current studies at Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group has proven from clinical trials that Chemo given before hormone blockage lives at least one year longer than chemo given after tumors become resistant to hormone blockage! Article #2 states that patients who received external beam radiation therapy, they found these patients were estimated to be 70 percent more likely to be diagnosed with a rectal cancer and 40 percent more likely for bladder cancer than the general public. Article #3 states that a immunotherapeutic agent has a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. Article #4 deals with a new biopsy method to identify aggressive PCa cancers.
1) Men with metastatic prostate cancer may live longer with chemo first ( 2 June 2014)
” Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group say the dramatic results are likely to change current standard practice, which has been routine since the 1950s. In a clinical trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer who received chemotherapy straight away alongside hormone-blocking therapy lived more than a year longer than men who followed the standard treatment – which is to wait until the tumors have become resistant to hormone therapy before receiving chemotherapy”. Full Article Here: Men with metastatic prostate cancer may live longer
2) Risk of secondary cancers increased following radiation for prostate cancer (3 June 2014 )
“Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center. As a whole, men diagnosed with prostate cancer were at a lower risk of developing a second cancer. But when researchers looked at patients who received external beam radiation therapy, they found these patients were estimated to be 70 percent more likely to be diagnosed with a rectal cancer and 40 percent more likely for bladder cancer than the general public”. Full Story Here: Risk of secondary cancers increased following radiation
3) Immunotherapy for prostate cancer in sight (27 May 2014 )
“The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal The Lancet Oncology, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer”. Full Story Here: Immunotherapy for prostate cancer in sight
4) New biopsy method more accurately identifies men at low risk for prostate cancer ( 21 May 2014 )
“UCLA researchers found that conventional “blind” biopsy failed to reveal the true extent of presumed low-risk prostate cancers, and that when targeted biopsy was used, more than a third of these men had more aggressive cancers than they thought. Their aggressive cancers were not detected by conventional blind biopsy using ultrasound alone, and the men were referred to UCLA’s active surveillance program thinking they were at no immediate risk”. Full Story Here: New biopsy method
We are all “buying time” in life. Some of us get more and others pay more!!
The New Denver Men’s Club
Blog: https://newdenvermensclub.wordpress.com/ “Men Fighting Cancer To Win”